Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 12/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 12/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 11/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 11/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399611 | 0.87 | ADORA2A (0.49) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL22399690 | 0.87 | ADORA2A (0.49) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL22326753 | 0.85 | ADORA2A (0.46) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL6363729 | 0.83 | ADORA2A (0.57) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL13239639 | 0.81 | ADORA2A (0.54) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL19350814 | 0.79 | ADORA2A (0.48) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL13239634 | 0.79 | ADORA2A (0.51) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL24145093 | 0.77 | CDK1 (0.53) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL15763397 | 0.77 | CDK1 (0.47) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL4379586 | 0.77 | ADORA1 (0.56) | ADORA2AADORA1CDK1TAAR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA2B 827/4885ADORA1 446/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA2B 686/4885ADORA1 344/4885 |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA2A 102/4885ADORA2B 387/4885ADORA1 163/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA2B 144/4885ADORA1 32/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | ADORA2A 216/4885ADORA2B 859/4885ADORA1 884/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ADORA2A 102/4885ADORA2B 387/4885ADORA1 163/4885 |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | ADORA2A 891/4885ADORA2B 1071/4885ADORA1 2027/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA2B 686/4885ADORA1 344/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA2A 69/4885ADORA2B 147/4885ADORA1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.